A New Way to Help Detect Cancer
DELFI’s rigorous clinical trial program produces evidence that our fragmentomics technology and products are suited to make cancer less deadly by helping make early detection accessible to all.
L101 - Groundbreaking Validation of the FirstLook Lung Test
In this case control study, participants with and without lung cancer were enrolled and provided blood samples to develop the FirstLook™ Lung test. The primary objective of the study was to train and validate a high performing blood-based lung cancer screening test for lung cancer early detection.
STATUS: The results of the L101 trial have been published in Cancer Discovery. Enrollment is closed.
CASCADE-LUNG (Cancer Screening Assay using DELFI) - L201
CASCADE-LUNG is a prospective cohort validation study of the FirstLook™ Lung test in individuals eligible for lung cancer screening. This large-scale study will help determine the ability of our simple, blood-based screening technology to detect lung cancer accurately and reliably.
STATUS: Enrollment is closed.
L301 - FIRSTLUNG
FIRSTLUNG is a prospective, cluster randomized controlled trial to observe the impact of the FirstLook™ Lung cancer screening test on lung cancer screening utilization in primary care practices. Approximately 62 practices are expected to be enrolled.
STATUS: Enrollment is closed.